Literature DB >> 31990804

Effect of Vaginal Lactobacillus Species on Escherichia coli Growth.

Patricia L Hudson, Kristin J Hung, Agnes Bergerat1, Caroline Mitchell.   

Abstract

OBJECTIVES: Lactobacillus probiotics have been proposed as an antibiotic-sparing prevention strategy for urinary tract infections (UTIs). Our objective was to examine the relative ability of the 4 most common vaginal Lactobacillus species to inhibit the growth of Escherichia coli, the most common cause of UTIs.
METHODS: Conditioned media (CM) was created from 4 laboratory strains of Lactobacillus species: Lactobacillus crispatus, Lactobacillus jensenii, Lactobacillus gasseri, and Lactobacillus iners, and 6 clinical strains of L. crispatus. One laboratory strain of E. coli was cocultured with each CM, as well as with various acidic solutions. Three clinical strains of E. coli from women with acute cystitis were cocultured with the CM from a laboratory strain of L. crispatus. Bacterial growth was compared between experimental variants and media control using analysis of variance.
RESULTS: Growth of E. coli was inhibited by CM from L. crispatus, L. jensenii, and L. gasseri, but not L. iners. The magnitude of inhibition was correlated with the pH of the individual CM and the concentration of D-lactic acid. Different acids inhibited E. coli growth in proportion to the pH of the acid solution. Similar levels of inhibition were seen when L. crispatus was incubated with clinical E. coli strains as with laboratory E. coli.
CONCLUSIONS: Three of the most common vaginal Lactobacillus species inhibit E. coli growth, likely through creating a low pH environment. However, L. iners, one of the most common species found after menopause, does not. These findings might be leveraged to more effectively manage UTIs.

Entities:  

Mesh:

Year:  2020        PMID: 31990804     DOI: 10.1097/SPV.0000000000000827

Source DB:  PubMed          Journal:  Female Pelvic Med Reconstr Surg        ISSN: 2151-8378            Impact factor:   2.091


  7 in total

1.  Transcriptomic Analysis of E. coli after Exposure to a Sublethal Concentration of Hydrogen Peroxide Revealed a Coordinated Up-Regulation of the Cysteine Biosynthesis Pathway.

Authors:  Myriam Roth; Vincent Jaquet; Sylvain Lemeille; Eve-Julie Bonetti; Yves Cambet; Patrice François; Karl-Heinz Krause
Journal:  Antioxidants (Basel)       Date:  2022-03-28

2.  Vaginal treatment with lactic acid gel delays relapses in recurrent urinary tract infections: results from an open, multicentre observational study.

Authors:  Ruth Diebold; Bettina Schopf; Holger Stammer; Werner Mendling
Journal:  Arch Gynecol Obstet       Date:  2021-03-27       Impact factor: 2.344

3.  Draft Genome Sequence of Lactobacillus mulieris UMB9245, Isolated from the Female Bladder.

Authors:  Lidia Ramotowski; Taylor Miller-Ensminger; Adelina Voukadinova; Alan J Wolfe; Catherine Putonti
Journal:  Microbiol Resour Announc       Date:  2020-05-14

4.  Draft Genome Sequence of Lactobacillus jensenii UMB0836, Isolated from the Female Bladder.

Authors:  Isaac Rivera; Taylor Miller-Ensminger; Adelina Voukadinova; Alan J Wolfe; Catherine Putonti
Journal:  Microbiol Resour Announc       Date:  2020-05-21

5.  Draft Genome Sequence of Lactobacillus jensenii UMB0847, Isolated from the Female Urinary Tract.

Authors:  Ella West-Pelak; Taylor Miller-Ensminger; Adelina Voukadinova; Alan J Wolfe; Catherine Putonti
Journal:  Microbiol Resour Announc       Date:  2020-05-14

6.  In-depth insights into cervicovaginal microbial communities and hrHPV infections using high-resolution microbiome profiling.

Authors:  Mariano A Molina; Karolina M Andralojc; Martijn A Huynen; William P J Leenders; Willem J G Melchers
Journal:  NPJ Biofilms Microbiomes       Date:  2022-09-28       Impact factor: 8.462

7.  Comparative Genomic Study of Lactobacillus jensenii and the Newly Defined Lactobacillus mulieris Species Identifies Species-Specific Functionality.

Authors:  Catherine Putonti; Jason W Shapiro; Adriana Ene; Oleksandra Tsibere; Alan J Wolfe
Journal:  mSphere       Date:  2020-08-12       Impact factor: 4.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.